Cargando…

The anticancer effect of recombinant LukS-PV protein and silver nanoparticles loaded with this protein

LukS-PV is a component of Panton-Valentine leucocidin (PVL) and is secreted by Staphylococcus aureus. Silver nanoparticles exhibit considerable potential as anticancer agents and drug delivery systems. Drug delivery is a way to deliver medicinal combinations to achieve a beneficial therapeutic effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Haghighatafshar, Hafizeh, Golestani Eimani, Bahram, Moazamian, Elham, Amani, Jafar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250288/
https://www.ncbi.nlm.nih.gov/pubmed/37289339
http://dx.doi.org/10.1186/s13568-023-01558-3
_version_ 1785055724434358272
author Haghighatafshar, Hafizeh
Golestani Eimani, Bahram
Moazamian, Elham
Amani, Jafar
author_facet Haghighatafshar, Hafizeh
Golestani Eimani, Bahram
Moazamian, Elham
Amani, Jafar
author_sort Haghighatafshar, Hafizeh
collection PubMed
description LukS-PV is a component of Panton-Valentine leucocidin (PVL) and is secreted by Staphylococcus aureus. Silver nanoparticles exhibit considerable potential as anticancer agents and drug delivery systems. Drug delivery is a way to deliver medicinal combinations to achieve a beneficial therapeutic effect. In the current study, recombinant LukS-PV protein-loaded silver nanoparticles were prepared and their cytotoxicity effect was analyzed on human breast cancer cells and human normal embryonic kidneys cells by MTT assay. Apoptosis was investigated by staining with Annexin V/propidium iodide. The recombinant LukS-PV protein-loaded silver nanoparticles showed dose‐dependent cytotoxicity and induced apoptosis in the MCF7 cells and had a lesser effect on HEK293 cells. After 24 h exposure to the recombinant LukS-PV protein-loaded silver nanoparticles (IC50), Annexin V-FITC/PI FCM revealed that 33.2% of MCF7 cells were apoptotic. In conclusion, recombinant LukS-PV protein-loaded silver nanoparticles probably cannot be a better alternative for the targeted healing approaches to cancer therapies. Hence, it is suggested that silver nanoparticles could be utilized as a delivery system for releasing toxins into cancer cells.
format Online
Article
Text
id pubmed-10250288
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-102502882023-06-10 The anticancer effect of recombinant LukS-PV protein and silver nanoparticles loaded with this protein Haghighatafshar, Hafizeh Golestani Eimani, Bahram Moazamian, Elham Amani, Jafar AMB Express Original Article LukS-PV is a component of Panton-Valentine leucocidin (PVL) and is secreted by Staphylococcus aureus. Silver nanoparticles exhibit considerable potential as anticancer agents and drug delivery systems. Drug delivery is a way to deliver medicinal combinations to achieve a beneficial therapeutic effect. In the current study, recombinant LukS-PV protein-loaded silver nanoparticles were prepared and their cytotoxicity effect was analyzed on human breast cancer cells and human normal embryonic kidneys cells by MTT assay. Apoptosis was investigated by staining with Annexin V/propidium iodide. The recombinant LukS-PV protein-loaded silver nanoparticles showed dose‐dependent cytotoxicity and induced apoptosis in the MCF7 cells and had a lesser effect on HEK293 cells. After 24 h exposure to the recombinant LukS-PV protein-loaded silver nanoparticles (IC50), Annexin V-FITC/PI FCM revealed that 33.2% of MCF7 cells were apoptotic. In conclusion, recombinant LukS-PV protein-loaded silver nanoparticles probably cannot be a better alternative for the targeted healing approaches to cancer therapies. Hence, it is suggested that silver nanoparticles could be utilized as a delivery system for releasing toxins into cancer cells. Springer Berlin Heidelberg 2023-06-08 /pmc/articles/PMC10250288/ /pubmed/37289339 http://dx.doi.org/10.1186/s13568-023-01558-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Haghighatafshar, Hafizeh
Golestani Eimani, Bahram
Moazamian, Elham
Amani, Jafar
The anticancer effect of recombinant LukS-PV protein and silver nanoparticles loaded with this protein
title The anticancer effect of recombinant LukS-PV protein and silver nanoparticles loaded with this protein
title_full The anticancer effect of recombinant LukS-PV protein and silver nanoparticles loaded with this protein
title_fullStr The anticancer effect of recombinant LukS-PV protein and silver nanoparticles loaded with this protein
title_full_unstemmed The anticancer effect of recombinant LukS-PV protein and silver nanoparticles loaded with this protein
title_short The anticancer effect of recombinant LukS-PV protein and silver nanoparticles loaded with this protein
title_sort anticancer effect of recombinant luks-pv protein and silver nanoparticles loaded with this protein
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250288/
https://www.ncbi.nlm.nih.gov/pubmed/37289339
http://dx.doi.org/10.1186/s13568-023-01558-3
work_keys_str_mv AT haghighatafsharhafizeh theanticancereffectofrecombinantlukspvproteinandsilvernanoparticlesloadedwiththisprotein
AT golestanieimanibahram theanticancereffectofrecombinantlukspvproteinandsilvernanoparticlesloadedwiththisprotein
AT moazamianelham theanticancereffectofrecombinantlukspvproteinandsilvernanoparticlesloadedwiththisprotein
AT amanijafar theanticancereffectofrecombinantlukspvproteinandsilvernanoparticlesloadedwiththisprotein
AT haghighatafsharhafizeh anticancereffectofrecombinantlukspvproteinandsilvernanoparticlesloadedwiththisprotein
AT golestanieimanibahram anticancereffectofrecombinantlukspvproteinandsilvernanoparticlesloadedwiththisprotein
AT moazamianelham anticancereffectofrecombinantlukspvproteinandsilvernanoparticlesloadedwiththisprotein
AT amanijafar anticancereffectofrecombinantlukspvproteinandsilvernanoparticlesloadedwiththisprotein